Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2005
12/15/2005US20050276812 Antibody-drug conjugates and methods
12/15/2005US20050276810 Cis-4-hydroxy-L-proline (CHP) together with bevacizumab for targeted treatment of cell proliferative disorders
12/15/2005US20050276789 Immunostimulatory oligonucleotides and uses thereof
12/15/2005US20050276757 Methods of using ZC1 and ZC3 kinase substrate phosphorylation as biomarkers
12/15/2005US20050276754 Bridged aromatic substituted amine ligands with donor atoms
12/15/2005US20050274671 Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid
12/15/2005DE102004026026A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia
12/15/2005CA2836987A1 Chimeric adenoviruses for use in cancer treatment
12/15/2005CA2572453A1 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
12/15/2005CA2572451A1 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005CA2569277A1 Method for treating abnormal cell growth
12/15/2005CA2569266A1 Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
12/15/2005CA2568718A1 Tetrahydropyridothiophenes for use in the treatment of cancer
12/15/2005CA2568641A1 Sustained release composition
12/15/2005CA2568523A1 Process to prepare camptothecin derivatives
12/15/2005CA2568415A1 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins
12/15/2005CA2568163A1 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
12/15/2005CA2567901A1 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member
12/15/2005CA2567887A1 Method for screening and compositions for treating cancers
12/15/2005CA2567883A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
12/15/2005CA2567852A1 Treatment with cisplatin and an egfr-inhibitor
12/15/2005CA2567838A1 Treatment of cancer in pediatric patients
12/15/2005CA2567836A1 Treatment with gemcitabine and an egfr-inhibitor
12/15/2005CA2567832A1 Quinazoline derivatives as erbb receptor tyrosine kinases
12/15/2005CA2567648A1 Novel tetrahydropyridothiophenes
12/15/2005CA2567520A1 Maytansinoid-antibody conjugates
12/15/2005CA2566975A1 Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents
12/15/2005CA2566974A1 Treatment with oxaliplatin and an egfr-inhibitor
12/15/2005CA2566971A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005CA2566886A1 Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
12/15/2005CA2565968A1 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
12/15/2005CA2563831A1 Monocyclic heterocycles as kinase inhibitors
12/15/2005CA2563445A1 Compositions and methods for modulating vascular development
12/15/2005CA2561861A1 Antibodies to angiogenesis inhibiting domains of cd148
12/14/2005EP1605053A1 Use of adenoviruses mutated in the VA genes for cancer treatment
12/14/2005EP1604983A1 Receptor antagonist
12/14/2005EP1604688A1 Stabilised mRNA with increased G/C-content and optimised codon usage for gene therapy
12/14/2005EP1604687A1 Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
12/14/2005EP1604682A1 Gonadal function improving agents
12/14/2005EP1604673A1 Auxiliary agent to be used in cancer therapy by dielectric heating and cancer therapy method
12/14/2005EP1604665A1 C-kit kinase inhibitor
12/14/2005EP1604009A2 Method for identifying risk of melanoma and treatments thereof
12/14/2005EP1603942A2 Regulation of gene expression
12/14/2005EP1603930A1 Protein-bound derivatives of platinum complexes containing cyclobutane 1.1-dicarboxyllate ligands
12/14/2005EP1603919A1 7-imino derivatives of camptothecin having antitumor activity
12/14/2005EP1603898A2 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
12/14/2005EP1603885A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors
12/14/2005EP1603879A2 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
12/14/2005EP1603860A2 Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
12/14/2005EP1603598A2 Radiolabeled conjugates based on substance p and the uses thereof
12/14/2005EP1603584A1 Aplidine for multiple myeloma treatment
12/14/2005EP1603576A1 Use of adenosine receptor agonists in therapy
12/14/2005EP1603575A2 Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
12/14/2005EP1603571A2 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
12/14/2005EP1603570A2 Aminoheteroaryl compounds as protein kinase inhibitors
12/14/2005EP1603566A1 Use of isoquinoline derivatives for treating cancer and map kinase related diseases
12/14/2005EP1603563A1 Resonance modulator for diagnosis and therapy
12/14/2005EP1603561A2 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor
12/14/2005EP1603557A2 Synthesis of peloruside a and analogs thereof for use as antitumor agents
12/14/2005EP1603555A2 Halogenated triptolide derivatives as immunomodulators and anticancer agents
12/14/2005EP1603543A1 Therapeutic compositions
12/14/2005EP1603542A1 Treatment and/or prevention of non-viral epithelial damage
12/14/2005EP1603541A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
12/14/2005EP1534283B1 Formulation of liposomal derivatives of phenylalanine
12/14/2005EP1527084A4 Promoters exhibiting endothelial cell specificity and methods of using same
12/14/2005EP1492766A4 Improved cc-1065 analog synthesis
12/14/2005EP1439847A4 Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
12/14/2005EP1427709B1 3-substituted-4-pyrimidone derivatives
12/14/2005EP1414859B1 Anti-ssrp-1 monoclonal antibodies and hybridomas producing said antibodies
12/14/2005EP1405074A4 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/14/2005EP1370144A4 Noninvasive measurements of chemical substances
12/14/2005EP1261583B1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/14/2005EP1242104B1 Process of obtaining thylakoids from plants, pure thylakoids and use thereof
12/14/2005EP1222175B1 4,5-disubstituted-2-aminopyrimidines
12/14/2005EP1082103B1 Spill resistant pharmaceutical compositions
12/14/2005EP1007714B1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
12/14/2005EP0927045B1 Tumor homing molecules, conjugates derived therefrom, and methods of using same
12/14/2005EP0506830B1 Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
12/14/2005CN1708540A High-molecular weight derivatives of camptothecins
12/14/2005CN1708495A Heterocyclic compounds and antitumor drugs containing the same as the active ingredient
12/14/2005CN1708490A Aminated isoflavonoid derivatives and uses thereof
12/14/2005CN1708480A Carotenoid analogs for the inhibition and amelioration of disease
12/14/2005CN1708315A Anti-tumor combinations comprising proteins and chemotherapeutics
12/14/2005CN1708297A Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
12/14/2005CN1708296A Combinations of anti-cancer agents
12/14/2005CN1708294A Combination of a CDK inhibitor and mitoxantrone
12/14/2005CN1706955A Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
12/14/2005CN1706855A Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
12/14/2005CN1706838A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
12/14/2005CN1231491C Mammal telomerase
12/14/2005CN1231484C Benzo [b] pyran-[3,2-h] acridinyl-7-one compounds, their prepn and medicine composition containing them
12/14/2005CN1231479C Naphthostyrils compounds
12/14/2005CN1231474C Salts of aiso thiazole-4-carboxamide and their use as anti-hyperproliferatin agents
12/14/2005CN1231471C 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhbitors of cell-cycle kinases
12/14/2005CN1231466C New piperidine derivatives
12/14/2005CN1231465C Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
12/14/2005CN1231458C Novel aryloxy-alkyl-dialkylamines compound
12/14/2005CN1231439C Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
12/14/2005CN1231264C Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
12/14/2005CN1231261C Compound alliin enteric solubility capsule
1 ... 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 ... 2211